United Kingdom Epigenetics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents and Kits, Antibodies, ChiP-seq Kits, Bisulfite Conversion Kits, Whole Genome Amplification Kits, RNA Sequencing Kits, Others), By Technology (NDNA Methylation, Histone Methylation, Histone Acetylation, Large non-coding RNA, MicroRNA modification, Others), By Application (Oncology, Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Others), By End Use (Academic Research, Clinical Research, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies) and Forecasts, 2026-2034

United Kingdom Epigenetics Market Size

The United Kingdom epigenetics market size was valued at USD 884 million in 2025 and is projected to grow from USD 971.87 million in 2026 to reach USD 2074.22 million by 2034, growing at a CAGR of 9.94% during the forecast period 2026–2034.

In recent years, there has been a rise in the cases of chronic diseases like CVDs, cancer, neurodegenerative conditions, etc, in the UK owing to the inclination of people towards unhealthy diets and sedentary lifestyles. This rise in the number of chronic disease cases is anticipated to boost the UK epigenetics market. Moreover, the market players in the region are collaborating with each other to enhance their market share, thereby creating opportunities for market growth.

Product Insights

The United Kingdom epigenetics market is divided into instruments, reagents and kits, enzymes, software, and services. The reagents and kits segment dominates the global market and is projected to exhibit a CAGR of 16.3% over the forecast period. The reagents and kits segment is a crucial component of the UK epigenetics market, providing essential tools for epigenetic research and analysis. These include DNA and RNA modification enzymes, histone modification antibodies, bisulfite conversion kits, and methylation detection assays. Suppliers in this segment continually innovate to meet the evolving needs of researchers, offering reliable products that ensure accuracy and reproducibility in epigenetic studies.

Request Customizationto receive a tailored report.

Application Insights

The UK epigenetics market is segmented into oncology, autoimmune diseases, metabolic diseases, CNS/pain diseases, cardiovascular diseases, and others. The oncology segment is estimated to own the highest market share and grow at a CAGR of 16.1% over the forecast period. The oncology segment within the epigenetics market for united kingdom focuses on utilizing epigenetic mechanisms for cancer diagnosis, prognosis, and treatment. Epigenetic alterations play a pivotal role in tumorigenesis, offering insights into cancer biology and therapeutic targets. Companies are investing in developing epigenetic drugs targeting specific cancer-associated epigenetic changes, aiming to improve patient outcomes and overcome drug resistance in various malignancies.

End-Users Insights

The UK epigenetics market is bifurcated into pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROS), and others. The pharmaceutical and biotechnology companies contribute to the largest market share and is anticipated to exhibit a CAGR of 16.5% over the forecast period. Pharmaceutical and biotechnology companies are actively engaged in research and development efforts to discover and develop novel epigenetic therapies for various diseases, including cancer, neurological disorders, and autoimmune conditions. They leverage their expertise in drug discovery, clinical development, and commercialization to bring epigenetic drugs to market.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The United Kingdom epigenetics market is a significant part of the European epigenetics landscape, which is characterized by high levels of research activity and substantial funding.

• For instance, in June 2022, Base Genomics, a spinout from the University of Oxford, received a seed round of €10.1M for funding its debut. The company aims to enhance cancer detection by analyzing epigenetic alterations in tumor DNA found in the bloodstream.

Also, within the UK, regions such as London, Cambridge, and Oxford are notable hubs for biotech and epigenetic research, supported by world-class universities and research institutions.

Moreover, the academic institutions in this region are also striving hard in the market to establish their foothold in the field of epigenetics.

• For instance, in January 2024, Queen Mary University established a new Epigenetics Hub with the purpose of detecting diseases at an early stage.

The newly established Epigenetics Hub, which has received funding from Barts Charity, combines the exceptional knowledge and proficiency of both organizations in the fields of epigenetics and artificial intelligence. The objective is to extract the data provided by cell-free DNA using 'liquid biopsies' - an easy and affordable blood test. This method has the potential to facilitate the early detection of several illnesses, including cardiovascular, kidney, and liver disease, cancer, aging, and pregnancy difficulties.

Thus, the above factors are anticipated to boost the UK epigenetics market growth.

List of Key and Emerging Players in United Kingdom Epigenetics Market